Albanese A, Bhatia K, Bressman SB, Delong MR, Fahn S, Fung VS, et al. Phenomenology and classification of dystonia: a consensus update. Mov Disord. 2013;28(7):863–73.
Article
PubMed
PubMed Central
Google Scholar
Perlmutter JS, Mink JW. Dysfunction of dopaminergic pathways in dystonia. Adv Neurol. 2004;94:163–70.
PubMed
Google Scholar
Di Giuda D, Camardese G, Bentivoglio AR, Cocciolillo F, Guidubaldi A, Pucci L, et al. Dopaminergic dysfunction and psychiatric symptoms in movement disorders: a 123I-FP-CIT SPECT study. Eur J Nucl Med Mol Imaging. 2012;39(12):1937–48.
Article
PubMed
Google Scholar
Horstink CA, Praamstra P, Horstink MW, Berger HJ, Booij J, van Royen EA. Low striatal D2 receptor binding as assessed by [123I]IBZM SPECT in patients with writer’s cramp. J Neurol Neurosurg Psychiatry. 1997;62(6):672–3.
Article
CAS
PubMed
PubMed Central
Google Scholar
Zoons E, Tijssen MA, Dreissen YE, Speelman JD, Smit M, Booij J. The relationship between the dopaminergic system and depressive symptoms in cervical dystonia. Eur J Nucl Med Mol Imaging. 2017;44(8):1375–82.
Article
CAS
PubMed
PubMed Central
Google Scholar
Smit M, Kuiper A, Han V, Jiawan VC, Douma G, van Harten B, et al. Psychiatric co-morbidity is highly prevalent in idiopathic cervical dystonia and significantly influences health-related quality of life: results of a controlled study. Parkinsonism Relat Disord. 2016;30:7–12.
Article
CAS
PubMed
Google Scholar
Ruhe HG, Booij J, Reitsma JB, Schene AH. Serotonin transporter binding with [123I]beta-CIT SPECT in major depressive disorder versus controls: effect of season and gender. Eur J Nucl Med Mol Imaging. 2009;36(5):841–9.
Article
CAS
PubMed
Google Scholar
Spies M, Knudsen GM, Lanzenberger R, Kasper S. The serotonin transporter in psychiatric disorders: insights from PET imaging. Lancet Psychiatry. 2015;2(8):743–55.
Article
PubMed
Google Scholar
Kambeitz JP, Howes OD. The serotonin transporter in depression: meta-analysis of in vivo and post mortem findings and implications for understanding and treating depression. J Affect Disord. 2015;186:358–66.
Article
CAS
PubMed
Google Scholar
Leo RJ. Movement disorders associated with the serotonin selective reuptake inhibitors. J Clin Psychiatry. 1996;57(10):449–54.
Article
CAS
PubMed
Google Scholar
Assmann B, Kohler M, Hoffmann GF, Heales S, Surtees R. Selective decrease in central nervous system serotonin turnover in children with dopa-nonresponsive dystonia. Pediatr Res. 2002;52(1):91–4.
Article
CAS
PubMed
Google Scholar
Naumann M, Gotz M, Reiners K, Lange KW, Riederer P. Neurotransmitters in CSF of idiopathic adult-onset dystonia: reduced 5-HIAA levels as evidence of impaired serotonergic metabolism. J Neural Transm (Vienna). 1996;103(8-9):1083–91.
Article
CAS
Google Scholar
Kurian MA, Gissen P, Smith M, Heales S Jr, Clayton PT. The monoamine neurotransmitter disorders: an expanding range of neurological syndromes. Lancet Neurol. 2011;10(8):721–33.
Article
CAS
PubMed
Google Scholar
Welsh JP, Placantonakis DG, Warsetsky SI, Marquez RG, Bernstein L, Aicher SA. The serotonin hypothesis of myoclonus from the perspective of neuronal rhythmicity. Adv Neurol. 2002;89:307–29.
PubMed
Google Scholar
Rubio-Agusti I, Parees I, Kojovic M, Stamelou M, Saifee TA, Charlesworth G, et al. Tremulous cervical dystonia is likely to be familial: clinical characteristics of a large cohort. Parkinsonism Relat Disord. 2013;19(6):634–8.
Article
CAS
PubMed
PubMed Central
Google Scholar
MacGillivray L, Reynolds KB, Sickand M, Rosebush PI, Mazurek MF. Inhibition of the serotonin transporter induces microglial activation and downregulation of dopaminergic neurons in the substantia nigra. Synapse. 2011;65(11):1166–72.
Article
CAS
PubMed
Google Scholar
Yokoi F, Dang MT, Li J, Li Y. Myoclonus, motor deficits, alterations in emotional responses and monoamine metabolism in epsilon-sarcoglycan deficient mice. J Biochem. 2006;140(1):141–6.
Article
CAS
PubMed
Google Scholar
Booij J, Kemp P. Dopamine transporter imaging with [(123)I]FP-CIT SPECT: potential effects of drugs. Eur J Nucl Med Mol Imaging. 2008;35(2):424–38.
Article
CAS
PubMed
Google Scholar
Tarsy D. Comparison of clinical rating scales in treatment of cervical dystonia with botulinum toxin. Mov Disord. 1997;12(1):100–2.
Article
CAS
PubMed
Google Scholar
Tsui JK, Eisen A, Stoessl AJ, Calne S, Calne DB. Double-blind study of botulinum toxin in spasmodic torticollis. Lancet. 1986;2(8501):245–7.
Article
CAS
PubMed
Google Scholar
Frucht SJ, Leurgans SE, Hallett M, Fahn S. The Unified Myoclonus Rating Scale. Adv Neurol. 2002;89:361–76.
PubMed
Google Scholar
Booij J, Habraken JB, Bergmans P, Tissingh G, Winogrodzka A, Wolters EC, et al. Imaging of dopamine transporters with iodine-123-FP-CIT SPECT in healthy controls and patients with Parkinson’s disease. J Nucl Med. 1998;39(11):1879–84.
CAS
PubMed
Google Scholar
Koopman KE, la Fleur SE, Fliers E, Serlie MJ, Booij J. Assessing the optimal time point for the measurement of extrastriatal serotonin transporter binding with 123I-FP-CIT SPECT in healthy, male subjects. J Nucl Med. 2012;53(7):1087–90.
Article
CAS
PubMed
Google Scholar
Stoddart HA, Stoddart HF. New multidimensional reconstructions for the 12-detector, scanned focal point, single-photon tomograph. Phys Med Biol. 1992;37(3):579–86.
Article
Google Scholar
Stam MK, Booij J, de Bruin K, de Wit T. Validation of a brain-dedicated SPECT camera. Eur J Nucl Med Mol Imag. 2014;41(Suppl 2):S378.
Google Scholar
Booij J, Tissingh G, Boer GJ, Speelman JD, Stoof JC, Janssen AG, et al. [123I]FP-CIT SPECT shows a pronounced decline of striatal dopamine transporter labelling in early and advanced Parkinson's disease. J Neurol Neurosurg Psychiatry. 1997;62(2):133–40.
Article
CAS
PubMed
PubMed Central
Google Scholar
de Win MM, Habraken JB, Reneman L, van den Brink W, den Heeten GJ, Booij J. Validation of [(123)I]beta-CIT SPECT to assess serotonin transporters in vivo in humans: a double-blind, placebo-controlled, crossover study with the selective serotonin reuptake inhibitor citalopram. Neuropsychopharmacology. 2005;30(5):996–1005.
Article
CAS
PubMed
Google Scholar
Innis RB, Cunningham VJ, Delforge J, Fujita M, Gjedde A, Gunn RN, et al. Consensus nomenclature for in vivo imaging of reversibly binding radioligands. J Cereb Blood Flow Metab. 2007;27(9):1533–9.
Article
CAS
PubMed
Google Scholar
Matsuoka K, Yasuno F, Shinkai T, Miyasaka T, Takahashi M, Kiuchi K, et al. Test-retest reproducibility of extrastriatal binding with 123I-FP-CIT SPECT in healthy male subjects. Psychiatry Res. 2016;258:10–5.
Article
PubMed
Google Scholar
Koch W, Unterrainer M, Xiong G, Bartenstein P, Diemling M, Varrone A, et al. Extrastriatal binding of [123I]FP-CIT in the thalamus and pons: gender and age dependencies assessed in a European multicentre database of healthy controls. Eur J Nucl Med Mol Imaging. 2014;41(10):1938–46.
Article
CAS
PubMed
Google Scholar
Zhang K, Zhu Y, Zhu Y, Wu S, Liu H, Zhang W, et al. Molecular, functional, and structural imaging of major depressive disorder. Neurosci Bull. 2016;32(3):273–85.
Article
CAS
PubMed
PubMed Central
Google Scholar
Munoz A, Li Q, Gardoni F, Marcello E, Qin C, Carlsson T, et al. Combined 5-HT1A and 5-HT1B receptor agonists for the treatment of L-DOPA-induced dyskinesia. Brain. 2008;131(Pt 12):3380–94.
Article
PubMed
Google Scholar
Roussakis AA, Politis M, Towey D, Piccini P. Serotonin-to-dopamine transporter ratios in Parkinson disease: relevance for dyskinesias. Neurology. 2016;86(12):1152–8.
Article
CAS
PubMed
Google Scholar
Ziebell M, Holm-Hansen S, Thomsen G, Wagner A, Jensen P, Pinborg LH, et al. Serotonin transporters in dopamine transporter imaging: a head-to-head comparison of dopamine transporter SPECT radioligands 123I-FP-CIT and 123I-PE2I. J Nucl Med. 2010;51(12):1885–91.
Article
PubMed
Google Scholar